This website has been developed by Besins Healthcare (UK) Ltd. This website has separate sections for healthcare professionals and patients who have been prescribed Testogel® 16.2 mg/g gel, within the UK.

Besins Healthcare is a pharmaceutical company specialising in the development of innovative drugs for the well-being of men and women throughout their life.

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Why Testogel® 16.2 mg/g gel?

Why Testogel

Prescribing

A prostate-specific antigen (PSA) test and digital rectal examination (DRE) is recommended.

It’s important to check if the patient has any of the following contraindications:

  • Cases of known or suspected prostatic cancer or breast carcinoma
  • Hypersensitivity to testosterone or any of the excipients
  • Active desire to have children
  • Severe chronic heart failure

When prescribing Testogel® 16.2 mg/g gel, treatment should only be started in adults as testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.2 A number of clinical tools, in addition to clinical guidelines, are available to help you decide when to treat patients.

  • Assess the response to therapy at 3, 6 and 12 months, and every 12 months thereafter
  • Aim for a target level of total testosterone 15-30 nmol/l to achieve optimal response
  • Monitor haematocrit before treatment, at 3-6 months, 12 months and every 12  months thereafter
  • Assess prostate health by PSA and digital  rectal examination before commencing testosterone therapy (TTh) followed by PSA at 3-6 months, 12 months and every 12 months thereafter
  • Assess cardiovascular risk before TTh is initiated and monitor cardiovascular risk factors throughout therapy

References

  1. Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, With Statements for UK Practice. J Sex Med. 2017;14(12):1504–1523.
  2. Testogel® 16.2 mg/g gel – Summary of Product Characteristics (SmPC) – https://www.medicines.org.uk/emc/product/8919/smpc. Accessed April 2021.
  3. Ullah MI, Riche DM, Koch CA. Transdermal testosterone replacement therapy in men. Drug Des Devel Ther. 2014;8:1010–112.

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: pharmacovigilance@besins-healthcare.com